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Abstract

Background and aim Assessment of volume of distribution (VD) and half-life (T½) values during
glomerular filtration rate (GFR) investigations is a useful quality control check. The aim of this
study was to derive reference data for VD and T½ and also to provide reference data for GFR
from studies performed using

99m

Tc-diethylenetriaminepentaacetic acid (

99m

Tc-DTPA).

Methods This was a retrospective study of 126 healthy potential kidney donors (age range 1859 years). GFR was evaluated from

99m

Tc-DTPA plasma clearance using the 2004 British

Nuclear Medicine Society guidelines. The association between VD and body surface area (BSA)
was assessed. T½ was correlated with age and with GFR. The correlation between BrochnerMortensen-corrected GFR (BM-GFRCorr) and age was evaluated.
Results

Uncorrected VD (L) was (10.1*BSA) ± 40.6% (p<0.01).

Corrected VD (L) was

(8.19*BSA) ± 34.4% (p<0.01). In individuals under the age of 40 years mean T ½ was 95.0 min ±
36.2%. In individuals 40 years and older, T ½ increased at a rate of 0.49 min/year (p=0.04). T ½
(min) was [9480*(1/BM-GFRCorr)] ± 35.1% (p<0.01). In individuals younger than 40 years the
correlation of BM-GFRCorr and age was not statistically significant (p=0.45) and mean GFR was
-1

2 -1

108 ml.min .(1.73m )
-1

± 27.5%. In individuals 40 years and older BM-GFRCorr was [170 2 -1

(1.55*age)] [ml.min .(1.73m ) ] ± 36.7% (p<0.001).

Conclusion Well defined reference data for VD and T½ can be used as quality control checks in
GFR investigations. In addition to these, reference data for GFR using
defined. This will enhance the interpretation of adult
Keywords:
ranges

99m

99m

99m

Tc-DTPA have been

Tc-DTPA GFR measurements.

Tc-DTPA, volume of distribution, half-life, glomerular filtration rate, reference
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Introduction

Glomerular filtration rate (GFR) is a standard measure of renal function. Although measuring
plasma inulin clearance remains the gold standard for determining GFR, this technique is rarely
used because it is time-consuming and difficult to perform [1,2]. An estimate of GFR can be
obtained by measuring creatinine clearance; however, this technique is inaccurate, especially in
cases of poor renal function [3,4]. Measurement of GFR using Nuclear Medicine techniques is
considered a suitable alternative with clearance of

51

51

Cr-ethylenediaminetetraacetic acid ( Cr-

EDTA) having been shown to be similar to that of inulin [5,6].
99m

Tc-diethylenetriaminepentaacetic acid (

to

51

99m

Tc-DTPA) is considered an acceptable alternative

Cr-EDTA [1,2]. It has the advantages of being inexpensive, widely available and the

radiation dose to the patient is low. It is also suitable for gamma camera imaging, allowing
simultaneous acquisition of a renogram for calculation of differential renal function. Clearance of
99m

Tc-DTPA has been shown to correlate well with

51

Cr-EDTA clearance [7].

In 2004 the British Nuclear Medicine Society (BNMS) published guidelines for the measurement
of GFR [2]. The authors recommended measuring the plasma clearance of either
99m

51

Cr-EDTA or

Tc-DTPA using the slope-intercept method with Brochner-Mortensen correction [2,8]. In the

clinical context this method provides a good compromise between accuracy and simplicity.
Nevertheless, careful attention to technique is warranted since methodological errors can be
introduced at a number of stages [9]. These include, amongst others, errors in height or weight
measurement, drawing up and injection of the patient dose, preparation or measurement of the
standard, and preparation or measurement of the plasma samples.

The slope-intercept method does, however, offer a number of opportunities for quality control of
the procedure [2]. Two parameters obtained during the calculation of GFR using the slopeintercept method are the volume of distribution (V D) and the half-life (T½) of the injected
radiopharmaceutical [8]. While being of limited value for predicting the GFR in isolation, these
values can be valuable to check for underlying methodological errors [2,10,11]. Using V D and T½
for this purpose requires clearly defined reference ranges for each of these parameters. The
BNMS guidelines provide a reference range for the uncorrected V D (L) as being linearly related
2

to body surface area (BSA) (m ) by the equation [2]:

VD (uncorrected) = (8*BSA) ± 25% (2SD)
This range for VD was obtained using
calculated using the formula:

(1)
51

Cr-EDTA. It applies to an uncorrected value for VD,
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VD (uncorrected) = A/C

(2)

where A is the administered activity and C the intercept at zero time obtained by back
extrapolation of the terminal exponential of the curve of activity per unit volume versus time [12,
Personal communication: G. Blake, King’s College London, UK].

The Medical Physics Department of University Hospital Southampton NHS Foundation Trust,
UK, found the corrected VD for
VD (corrected) = (6.61*BSA

1.218

99m

Tc-DTPA to be related to BSA by the equation [13]:

) ± 32% (2SD)

(3)

The values for VD were calculated using the equation:
VD (corrected) = BM-GFR / k

(4)

where BM-GFR is the Brochner-Mortensen-corrected GFR [8] and k is the slope of the terminal
exponential.

Equation 2 leads to an overestimation of the volume of distribution as it takes into account only
the terminal exponential of the plasma clearance curve after mixing has taken place between
the vascular and extravascular compartments [12]. The degree of overestimation is similar to
that found when calculating GFR by the slope-intercept method without Brochner-Mortensen
correction. The corrected volume of distribution, VD

(corrected)

(equation 4), although still an

approximation since it assumes k is the terminal exponential, tries to correct for the
overestimation.

A technique of measuring extracellular fluid volume (ECV) using a combination of the slope-only
and slope intercept methods has been described and validated [14,15]. Using this technique,
reference data for ECV have recently been described by Peters et al in a large multi-centre
study in the UK [16].
In the BNMS guidelines T½ is described as being “typically in the range” of 100-120 min in
adults [2]. However, to the authors’ knowledge no data has been published supporting the use
of the above or other reference ranges for V D and T½. Specifically, there is a lack of published
data for normal values of VD and T½ that have been determined using

99m

Tc-DTPA [17].

Reference data for GFR have been well-defined by Granerus [18], Hamilton et al [19], Grewal
and Blake [20], as well as by Peters et al [16]. Although previous studies have shown only a
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small difference in GFR values obtained using
published reference ranges for GFR using

99m

51

Cr-EDTA and

99m

Tc-DTPA [21,22], there are no

Tc-DTPA.

The aim of this study was to determine reference values for VD and T½ from GFR studies using
99m

Tc-DTPA in a healthy population. In addition, reference data for GFR using

99m

Tc-DTPA have

been defined for the study population.

Methods

Patient population:
This retrospective study included the GFR studies of all potential kidney donors referred to the
Nuclear Medicine Department of Tygerberg Hospital, Cape Town, South Africa, between
February 2007 and September 2012. In total 128 GFR studies were performed and 126 of these
were included in the study (69 females, 57 males; age range 18-59 years). Two studies were
excluded; one due to discrepancies with weight measurements and one as it was performed
using

51

Cr-EDTA. In 113 subjects a renogram was performed in combination with the GFR

study, while in 13 subjects the GFR study was performed on a different day to the renogram. All
potential donors underwent a screening process by the hospital’s Renal Unit. Subjects were
excluded if they had chronic diseases that could potentially affect renal function or that placed
them in a high-risk surgical category. Hypertension, diabetes mellitus and psychiatric illness
were considered absolute contraindications to kidney donation. The initial blood tests included
haematological and biochemical parameters (urea, creatinine, full blood count, liver function,
sodium, potassium, chloride, calcium, magnesium, inorganic phosphate, uric acid, glucose), as
well as serology for HIV, syphilis, hepatitis A, hepatitis B, hepatitis C, and cytomegalovirus. If
these tests were normal and the subject was considered a match based on ABO compatibility
and T-cell cross-matching, more specific renal screening was performed. GFR was estimated
from a plasma creatinine sample using either the Modification of Diet in Renal Disease (MDRD)
[23] or Cockgroft-Gault formula [24]. In addition, creatinine clearance was calculated from a 24hour urine collection, 24-hour urinary protein excretion was determined, and a spot urine
sample was collected to determine the protein-to-creatinine ratio. Only if the results of all tests
were normal were subjects referred to the Nuclear Medicine department for a renogram and
GFR study.

This work was approved by the Stellenbosch University Health Research Ethics Committee;
study number N10/05/177.

Measurement of GFR, VD and T½:
All GFR studies were performed based on the protocol described in the BNMS guidelines [2].
The subjects’ heights and weights were recorded and the BSA calculated using the Haycock

6

formula [25].

99m

Tc-DTPA (TechneScan® DTPA, Covidien) was injected intravenously. Labelling

efficiency was greater than 90% in all cases. The injection site was imaged to exclude
extravasation. The dose was approximately 40 MBq when only the GFR study was performed
on that visit, and about 400 MBq when the GFR study was combined with a renogram. The
patient and standard doses were accurately calibrated by weighing the syringes pre- and postinjection on a Precisa 620 C balance, without flushing the syringes or removing the needles.
Three 8 ml venous blood samples were drawn from the contralateral arm at 2, 3 and 4 hours
respectively. The exact time of injection and the time of drawing each sample were recorded to
the nearest minute. Samples were centrifuged immediately after being drawn. A standard was
prepared by withdrawing a similar dose of

99m

Tc-DTPA from the same kit and adding it to a half-

filled 100 ml flask, which was subsequently filled to the 100 ml mark with distilled water and
mixed. Two millilitres of this solution was pipetted into a second 100 ml flask that was filled and
mixed in a similar manner. The dilution volume of the standard was thus equivalent to 5 litres.
Duplicate 1 ml aliquots of plasma samples and standard were pipetted into counting tubes.
Background counts were recorded, followed by the counting of each sample in a Picker NaI(Tl)
well counter. All samples were counted sequentially in one sitting. Linearity of the well counter
was checked routinely and was acceptable, specifically at high count rates.

The GFR was calculated using the slope-intercept method as described in the 2004 BNMS
guidelines [2]. The natural logarithm of the plasma

99m

Tc-DTPA concentrations were plotted

against time. Linear regression analysis was used to determine the half-life (T½) and VD
(uncorrected). The

slope-intercept GFR (SI-GFR) was calculated using the equation [2]:

SI-GFR = VD (Uncorrected) x (0.693/T½)

(5)

The SI-GFR was then corrected for body surface area:
2

SI-GFRCorr = SI-GFR x (1.73/BSA m )

(6)

Subsequently, the mean Brochner-Mortensen (BM) equation was applied to correct for the
missing area under the curve from the fast exponential [2]:
BM-GFRCorr = 1.0004 x SI-GFRCorr – 0.00146 x SI-GFR

2
Corr

(7)

The coefficients used in this equation are an average of those in the adult [8] and paediatric
equations [26].

The absolute GFR was calculated by reversing the BSA correction:

7

2

BM-GFR = BM-GFRCorr x (BSA m /1.73)

(8)

For each GFR study the uncorrected VD was calculated using equation 2 and the corrected VD
was calculated using equation 4.

Using the methodology previously described [14-16], ECV-BSA (extracellular volume corrected
2

to a BSA of 1.73 m ) was calculated for each individual. Correction for BSA was reversed by
2

multiplication of ECV-BSA with BSA/1.73m to give ECV [16].

Defining reference ranges:
Values for VD, both uncorrected and corrected, were plotted against BSA. Using linear
regression analysis the correlation was determined between VD and BSA. Variability was
defined by calculating the standard error of the estimate of the regression analysis. This gives
the standard deviation of estimating VD from BSA. In this report the 95% confidence limits, or
two standard deviations, are expressed as a percentage relative to the mean V D value. These
results were compared to the accepted reference ranges described earlier (equations 1 and 3)
[2,13] and to the ECV-BSA data described by Peters et al [16].

In order to define reference data for T ½, the correlations of T½ and age as well as T½ and 1/BMGFRCorr were determined. Similarly, the association between BM-GFRCorr and age was
investigated using linear regression. Variability for these parameters was also described by the
relative two standard deviation, expressed as a percentage. The results of the BM-GFRCorr vs.
age correlation were compared to

51

Cr-EDTA reference ranges described by Granerus [18],

Hamilton [19] and Grewal and Blake [20] and to the mean values for GFR described by Peters
et al [16].

Deviations from BNMS guidelines
The protocol used in this study deviated from the BNMS guidelines in two aspects and steps
were taken to assess their impact on the calculated GFR and V D. Firstly, in 70 of the 126
studies, low counts were recorded for some of the samples. The BNMS guidelines state that,
where practical, a minimum of 10 000 counts should be obtained from each sample in order to
reduce statistical error [2]. The effect of this factor on the accuracy of the GFR and V D was
assessed by introducing simulated random error into the counts that were obtained from all
samples in all 126 studies. This was repeated 10 times and GFR and VD were calculated in
each instance. From this data, systematic, random and total error was estimated.

A second deviation from the BNMS guidelines was that no correction was performed for decay
of

99m

Tc during the counting process. In order to quantify the error introduced by not correcting

for radioactivity decay, an independent set of 26 GFR studies was evaluated. Counts obtained
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from all samples in these studies were higher than 10 000 and the exact time at which each
sample was counted was recorded. GFR and VD were then calculated for each study, with and
without decay correction. From this set of data the systematic, random and combined errors
were computed.

Results
2

The scatter graphs of the uncorrected VD (L) and corrected VD (L) as a function of the BSA (m )
are shown in figures 1 and 2 respectively with trendlines representing ± 2SD.
2

The correlation between VD (L), both uncorrected and corrected, and BSA (m ) was significant
(p < 0.001 for both correlations). Both were best described using linear functions:

VD (Uncorrected) = (10.1 * BSA) L ± 40.6% (2SD)

(9)

(RMSE = 3.70 L; 95% CI for the coefficient: 9.79 to 10.5 L).

VD (Corrected) = (8.19 * BSA) L ± 34.4% (2SD)

(10)

(RMSE = 2.53 L; 95% CI for the coefficient: 7.95 to 8.44 L).

In figure 1 the trendlines representing the upper and lower limits of the range described in the
BNMS guidelines (equation 1) [2] are displayed. Similarly, the trendlines representing the upper
and lower limits of the range described by University Hospital Southampton NHS Foundation
Trust, UK [13] are displayed in figure 2.
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Fig. 1
35.0
30.0

VD (uncorrected) (L)

25.0
Mean (current study)

20.0

+ 2SD (current study)
15.0

- 2SD (current study)

10.0

+ 2SD (BNMS)
- 2SD (BNMS)

5.0
0.0
1.25

1.45

1.65

1.85

2.05

2.25

2.45

BSA (m2)
Scatter graph of the uncorrected values of volume of distribution [VD (uncorrected)] in litres plotted as a function of BSA. The
central line represents equation 9, the upper and lower lines (dashes) represent ± 2SD (± 40.6%). The faint dotted lines
represent the upper and lower limits of the reference range described in BNMS guidelines (8*BSA ± 25%) (2SD) [2].
There is overlap of the two lines representing - 2SD.

Fig. 2
35.0
30.0

VD (corrected) (L)

25.0
Mean (current study)

20.0

+ 2SD (current study)
15.0

- 2SD (current study)

10.0

+ 2SD (Southampton)
- 2SD (Southampton)

5.0
0.0
1.25

1.45

1.65

1.85

2.05

2.25

2.45

BSA (m2)
Scatter graph of corrected values of volume of distribution [VD (corrected)] in litres plotted as a function of BSA. The central
line represents equation 10, the upper and lower lines (dashes) are ± 2SD (± 34.4%). The faint dotted lines represent
the upper and lower limits of the reference range determined by University Hospital Southampton (6.61*BSA1.218) ± 32%
(2SD) [13].
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2

Mean ECV normalised for BSA (ECV-BSA) was 12.7 ± 4.4 (2SD) L/1.73 m . ECV-BSA in men
2

2

was 13.5 ± 4.9 (2SD) L/1.73 m and in women 12.0 ± 3.5 (2SD) L/1.73 m .

The association between T½ (min) and age (years) was not statistically significant (p = 0.16), nor
was the association between T ½ (min) and age (years) in subjects under the age of 40 years (p
= 0.65). In this subgroup (< 40 years) the mean T ½ was 95.0 ± 36.2% (2SD). In subjects 40
years and older the association between T ½ and age was statistically significant (p = 0.046).
This bi-linear fit is illustrated in figure 3. Using linear regression the following equation describes
the association in subjects 40 years and older:

T½ = [(0.49*age) + 75.9] min ± 30% (2SD)

(11)

2

-1

The association between T ½ (min) and 1/BM-GFRCorr (min.(1.73m ).ml ) was statistically
significant (p < 0.001) and it is illustrated in the scatter graph in figure 4. Using linear regression
it was best described using the equation:

T½ = 9480*(1/BM-GFRCorr) min ± 35.1% (2SD)

(12)

Fig. 3
200.0
180.0
160.0

T1/2 (min)

140.0

< 40 years
>/= 40 years

120.0

mean

100.0

+ 2SD
80.0

- 2SD

60.0
40.0
10

20

30

40

50
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70

Age (years)
Scatter graph of T½ (min) plotted as a function of age (years). The central line represents the mean in individuals under
the age of 40 years and the equation-predicted-mean in individuals 40 years and older (equation 11). The upper and
lower lines are ± 2SD (± 36.2% in individuals < 40 years and ± 36.7% in individuals ≥ 40 years
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Fig. 4
250.0

T1/2 (min)

200.0

150.0
Mean
100.0

+ 2SD
- 2SD

50.0

0.0
0.005

0.010

0.015

0.020

1/BM-GFRCorr [min.(1.73m2)/ml]
Scatter graph of T½ (min) plotted as a function of (1/BM-GFRCorr) [min.(1.73m2).ml-1)]. The central line represents T½
fitted to equation 12 and the upper and lower lines represent ± 2SD (± 35.1%).

-1

2 -1

Figure 5 is the scatter graph of BM-GFRCorr [ml.min .(1.73m ) ] plotted as a function of age
(years). In individuals younger than 40 years the correlation was not statistically significant (p =
-1

2 -1

0.45). The mean GFR in this group was 108 ml.min .(1.73m ) ± 27.5% (2SD). In individuals 40
years and older the correlation between GFR and age was statistically significant (p < 0.001).
The following equation describes this association:
-1

2 -1

BM-GFRCorr = 170 – (1.55*age) [ml.min .(1.73m ) ] ± 36.7% (2SD)
-1

(13)
2 -1

Mean BM-GFRCorr in men was 107 ± 29.8 (2SD) [ml.min .(1.73m ) ] and in women 100.7 ±
-1

2 -1

35.8 (2SD) [ml.min .(1.73m ) ]. This difference was statistically significant (p = 0.04), however,
men were significantly younger than women, mean age 30.5 vs. 36.4 years (p = 0.003).
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Fig 5
160.0

BM-GFRCorr (ml/min/1.73m2)
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Scatter graph of BM-GFRCorr [ml.min-1.(1.73m2)-1] as a function of age (18-59 years) in 126 potential kidney donors.
GFR values were corrected for BSA and using the mean Brochner-Mortensen equation [2,8]. The central line represents
the mean GFR in individuals under the age of 40 years and the mean fitted to equation 13 in individuals 40 years and
older. The upper and lower lines represent ± 2SD (± 27.5% in individuals under the age of 40 years and 36.7% in
individuals older than 40).

Considering all 126 studies, the systematic and random errors (1SD) introduced to GFR data
through statistical noise were -0.19% and 2.97% respectively, and for VD, 0.64% and 10.19%
respectively. In the prospective series of 26 studies the systematic and random errors (1SD)
introduced to GFR data through not correcting for radioactivity decay were -0.12% and 1.81%
respectively, and for VD, -0.22% and 2.37% respectively. In this series the counting of all
samples was completed within 14 minutes (range 6 – 14 min, mean 9 min).

Discussion
In this study reference ranges for a South African adult population were determined for VD, T½
and GFR using

99m

Tc-DTPA and the slope-intercept method as described in the BNMS

Guidelines [2]. The slope-intercept method remains prone to methodological errors [5,6] and
various quality control checks have been proposed: the fit of the counts to a single exponential
can be assessed, either graphically or by checking that the correlation coefficient is greater than
0.985 [2]. Alternatively, slope-intercept GFR measurements can be checked using singlesample estimates [27,28] or using the slope-only technique [9,14].

13

VD and T½ are two quantities that are obtained during calculation of GFR using the slopeintercept method. The BNMS guidelines recommend reviewing these quantities as an additional
quality control check [2]. For this purpose it is necessary to compare values to normal values for
VD and T½ defined for the patient population and for the radiopharmaceutical used.
In the present study a reference range for uncorrected VD in litres was identified as (10.1 * BSA)
± 40.6% (2SD). These values are systematically higher and show greater variability than those
described in the BNMS guidelines (equation 1, fig. 1) [2]. Although the values for VD in the
BNMS guidelines were derived from GFR measurements using
demonstrated no significant difference in VD between

51

51

Cr-EDTA, previous studies

Cr-EDTA and

99m

Tc-DTPA [21, 29].

Therefore, it is believed that it is unlikely that the radiopharmaceutical justifies for the
differences between the BNMS range and the values in the current study.

In this study the reference range for corrected VD in litres was found to be (8.19 * BSA) ± 34.4%
(2SD). The variability for corrected VD (34.4%) is noted to be lower than for uncorrected V D
(40.6%). This is expected because uncorrected VD is overestimated relative to the true value
and the degree of overestimation depends on GFR. Thus a subject of a given size will have a
higher value for uncorrected VD if GFR is normal than if it is reduced. This GFR-related
variability of VD is reduced by applying a Brochner-Mortensen correction.
In this study the values for corrected VD are systematically higher than those reported by
University Hospital Southampton NHS Foundation Trust (equation 3, fig. 2) [13]. For example,
2

for a BSA of 1.73 m , the corrected VD using the Southampton equation would be 12.9 L whilst it
would be 14.2 L using equation 11, leading to a 9% higher value. However, considering that the
2SD error for the Southampton data is 32% and for the data in the current study it is 34.4%, the
difference in variability between the two centres is within the estimated error on the V D.
Radiopharmaceutical factors are even less likely to account for the differences in corrected VD
between this centre and Southampton University Hospitals NHS Trust. In fact, both centres
used TechneScan® DTPA, Covidien. This specifically excludes differences in protein binding of
different DTPA preparations as a cause for the higher values or greater variability seen in V D.
The study populations in the two centres differ. The Southampton data was obtained from a
general clinical GFR population, which included normal and abnormal GFRs and both children
and adults, while the data in this study was obtained from a carefully selected normal adult
population. This will affect the uncorrected values of VD. The overestimation of uncorrected VD
will be higher in the normal group compared to the mixed population as the GFR will on average
be higher. In terms of environmental and ethnic factors, the population in this study is likely to
be more diverse than a population originating from Southampton. The current study population

14

is heterogeneous, with roughly equal numbers of subjects of Caucasian, African and mixed
ancestry. It has been shown in previous studies that there are differences in muscle mass
amongst different ethnic groups and this may translate to differences in VD [30-32].
An additional factor contributing to the variability in the results for V D might have been
experimental error due to low counts; however, this is thought to play a minor role and it will be
discussed later in this section.

Using the technique described by Peters et al ECV-BSA was calculated for each subject [142

16]. The mean ECV-BSA was 12.7 ± 4.4 (2SD) L/1.73 m , whilst for males it was 13.5 ± 4.9
2

2

(2SD) L/1.73 m and females 12.0 ± 3.5 (2SD) L/1.73 m . These GFR values were corrected for
the one-pool assumption using the mean Brochner-Mortensen correction as recommended in
the BNMS guidelines [2]. When corrected using the adult Brochner-Mortensen equation [8],
2

2

ECV/BSA in males was 13.9 ± 5.1 (2SD) L/1.73 m and in females 12.3 ± 3.7 (2SD) L/1.73 m .
These values for ECV-BSA agree reasonably well with those described by Peters et al in their
recent multi-centre UK-based study [16].

The mean value for ECV in this study is 27% lower than the mean value for uncorrected VD.
This is in close agreement with previous work in which a difference of 30% was described [33].
The mean value for ECV-BSA in the current study is, however, also approximately 10% lower
than the mean value for corrected VD normalized for BSA. This is due to the approximation used
in this study that the slope of the second exponential is equal to the clearance constant. The
work of Bird et al [15] shows that the slope systematically underestimates the constant by about
10% leading to an overestimate in the volume of distribution.

Calculation of T½ may be used as a quality control check by comparing it against the value
expected for the subject’s GFR. The association between T ½ (min) and 1/BM-GFRCorr
2

-1

[min.(1.73m ).ml ] was statistically significant (p < 0.001) and T ½ (min) was found to be
[9480*(1/BM-GFRCorr)] ± 35.1%.
In the study by Grewal and Blake, the authors noted that it was apparent that there was a break
in the age dependence of GFR at approximately 40 years [20]. They found no statistically
significant correlation between GFR and age for individuals under the age of 40 years, while
there was a statistically significant decrease in GFR from the age of 40 years onward. In this
study a cut-off of 40-years was used based on this work and it supports that conclusion: for
individuals under the age of 40, the correlation between GFR and age was not statistically
significant (p = 0.45), while it was significant (p < 0.001) in individuals 40 years and older. In
-1

2 -1

individuals younger than 40 years the mean BM-GFRCorr was 108 ml.min .(1.73m ) . This is the
-1

2 -1

same as the 108 ml.min .(1.73m )

reported by Hamilton et al [19], but higher than the 103
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-1

2 -1

-1

2 -1

ml.min .(1.73m ) reported by Grewal and Blake [20] and the 105 ml.min .(1.73m ) reported
by Granerus and Aurell [18]. The slightly higher GFR is expected for DTPA compared to EDTA
[21-22]. In individuals 40 years and older, BM-GFRCorr was expressed by the linear relation 170
-1

2 -1

– (1.55*age) [ml.min .(1.73m ) ] ± 36.7% (2SD). In this study the reference curve predicts a
-1

2 -1

mean GFR at age 50 years of 93 ml.min .(1.73m ) . This is in good agreement with the mean
-1

2 -1

of 94 ml.min .(1.73m )
1

found by Grewal and Blake [20], but lower than the 98 ml.min

-

2 -1

.(1.73m ) in the Granerus and Aurell study [18]. The data in the subgroup 40 years and older

has to be interpreted with caution, however, as it comprised only 44 individuals and covered a
relatively limited age range compared to the other studies.

The results of Granerus and Aurell [18] and Hamilton et al [19] are not directly comparable due
to small differences in methodology. On the other hand, the current study is based on the
protocol described in the BNMS guidelines [2], as was the study by Grewal and Blake [20],
making it more appropriate for comparison.

It is accepted that GFR declines with age, although a cut-off age for the start of the decline is
difficult to establish as recently shown by Peters et al [16]. No clear age cut-off could be
identified in the current study, however a threshold of 40 years of age was chosen in
accordance with the cut-off age used in a previous study [20]. Due to a relatively small study
sample, individuals were not divided into groups based on gender, however, mean BM-GFRCorr
-1

2 -1

-1

2 -1

was 107.0 ± 14.9 (1SD) ml.min .(1.73m ) in men vs. 100.7 ± 17.9 (1SD) ml.min .(1.73m ) in
women. The difference was statistically significant (p = 0.04), however, the difference might be
explained by the fact that the male cohort was significantly younger than the female cohort
(mean age 30.5 versus 36.4 years, p = 0.002). These mean values for GFR in men and women
are higher than those described in the multi-centre UK study [16], but this can be explained by
two factors: firstly, the majority of GFR measurements (1783 of 1878) in the multi-centre study
were performed using

51

Cr-EDTA and secondly, the mean age of subjects in all the individual

centres was higher than the mean age of subjects in the current study. Due to the relatively
small study population, individuals in the current study could not be sub-divided into groups
based on other factors such as obesity as was done in the multi-centre study [16].

In another study by the same authors the coefficient of variation (CV) of ECV-BSA in normal
subjects was found to be useful in assessing departmental performance as it reflects the
‘technical robustness’ with which the department performs the GFR measurements [34]. The
authors suggest a range of 10-20% as acceptable. The CV for ECV-BSA in this study (using the
adult Brochner-Mortensen correction equation [8]) was 15%.

The BNMS guidelines state that, where practical, a minimum of 10 000 counts should be
obtained for each sample in order to reduce statistical errors [2]. In this study, 70 of the 126
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GFR studies contained samples with fewer than 10 000 counts. The systematic error (1SD) in
GFR and VD values due to counting error was found to be low (0.19% and 0.64% respectively).
As expected, the random error (1SD) was higher (GFR 2.97% and V D 10.19%). Another
deviation from the BNMS guidelines was that no correction was made for the decay of Tc-99m.
The resultant systematic error (1SD) was negligible in all cases (GFR -0.12% and VD -0.22%)
therefore it was ignored in further calculations. The random error (1SD) was larger (GFR 1.81%
and VD 2.37%). By assuming that the error measured in the 26 cases represented the error
introduced through not correcting for decay in all 126 studies, the combined random error of
noise and lack of decay correction could be calculated. This resulted in 3.5% for GFR and
10.5% for VD (1SD).
The components of the relatively high combined random error in V D were assessed further. In
the correlation of uncorrected VD against BSA, a 1SD error expressed as a percentage of the
mean VD is 20.3% (equation 9). Part of this variation will be genuine variability of V D with BSA,
y%, and part due to experimental error. The two components add in quadrature:
2

2

2

20.3 = y + 10.5

(14)

The real standard deviation variation of uncorrected VD with BSA, y, is therefore 17.4%.
Similarly, for corrected VD, a 1SD error expressed as a percentage of the mean is 17.2%
(equation 10) and the real standard deviation variation with BSA is 13.6%. These results show
that, because the error in VD is relatively large, the contribution of low counts and lack of decay
correction to this variability is small.

It is worth mentioning that a cohort of 126 studies is relatively small, therefore further larger
studies are recommended to better define reference data for GFR using

99m

Tc-DTPA. Secondly,

the age of all individuals fell between 18 and 59 years, with few over the age of 50, as these
were the subjects being considered as kidney donors. Ideally, a study of this nature should
include subjects over a wider range of ages, including individuals over the age of 60 years as
these are often the patients referred for GFR studies. Moreover, although the hospital’s
screening process for kidney donors is intensive, it may not have been rigorous enough to
exclude all subjects with mild renal pathology.

Having defined the variation of volume of distribution with body surface area and its expected
variation, this data may be used for quality control. Studies in which the value of VD lies outside
the expected limits for the subject’s BSA may be deemed fail the quality control (QC) test.
Considering the corrected VD data shown in Figure 2, two of the studies lie well away from the
2SD limits and therefore may be considered to fail the QC requirements. Using 2SD limits, 5%
of the studies will lie outside the limits due to natural statistical variation, therefore in practical
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use wider limits might be used e.g. 2.5 or 3 SD.

Several different methods of calculating

volume of distribution exist and it is therefore important that in using this parameter in quality
control values must be compared to the corresponding normal range for that particular
estimation of the volume. A similar test may be applied to the measured T½. This is compared to
the expected limits of T ½ for the subject’s normalized GFR and if it lies outside these, then the
study is deemed to fail the QC test (figure 4). One limitation of the current data in this respect is
that it only contains data from control subjects. To obtain a better fit for low GFR further data is
required.

Conclusion
This study has defined reference data for GFR, VD and T½ from GFR studies using

99m

Tc-DTPA

in a healthy South African adult population. VD and T½ values can provide useful quality control
checks for GFR studies performed using the slope-intercept method as described in the BNMS
guidelines [2]. Reference data for GFR will enhance the interpretation of adult

99m

Tc-DTPA GFR

measurements. The small difference in normal values for GFR in comparison to previous
studies using

51

Cr-EDTA is in agreement with previous publications.
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Legend to figures
Figure 1
Scatter graph of the uncorrected values of volume of distribution [VD (uncorrected)] in litres plotted as
a function of BSA. The central line represents equation 9, the upper and lower lines (dashes)
represent ± 2SD (± 40.6%). The faint dotted lines represent the upper and lower limits of the
reference range described in BNMS guidelines (8*BSA ± 25%) (2SD) [2]. There is overlap of the
two lines representing - 2SD.
Figure 2
Scatter graph of corrected values of volume of distribution [VD

(corrected)]

in litres plotted as a

function of BSA. The central line represents equation 10, the upper and lower lines (dashes) are
± 2SD (± 34.4%). The faint dotted lines represent the upper and lower limits of the reference
range determined by University Hospital Southampton (6.61*BSA

1.218

) ± 32% (2SD) [13].

Figure 3
Scatter graph of T½ (min) plotted as a function of age (years). The central line represents the
mean in individuals under the age of 40 years and the equation-predicted-mean in individuals
40 years and older (equation 11). The upper and lower lines are ± 2SD (± 36.2% in individuals <
40 years and ± 36.7% in individuals ≥ 40 years).
Figure 4
2

-1

Scatter graph of T½ (min) plotted as a function of (1/BM-GFRCorr) [min.(1.73m ).ml )]. The
central line represents T½ fitted to equation 12 and the upper and lower lines represent ± 2SD (±
35.1%).
Figure 5
-1

2 -

Scatter graph of BM-GFRCorr [ml.min .(1.73m ) 1] as a function of age (18-59 years) in 126
potential kidney donors. GFR values were corrected for BSA and using the mean BrochnerMortensen equation [2,8]. The central line represents the mean GFR in individuals under the
age of 40 years and the mean fitted to equation 13 in individuals 40 years and older. The upper
and lower lines represent ± 2SD (± 27.5% in individuals under the age of 40 years and 36.7% in
individuals older than 40).

